Entera Bio amends ATM sales agreement with B. Riley Securities to reflect loss of foreign private issuer status

Entera Bio Ltd.

Entered into Amended and Restated At Market Issuance Sales Agreement with B. Riley Securities dated May 27, 2022.
Amendment made to reflect that Entera Bio is no longer a foreign private issuer.
All material terms of the original agreement remain unchanged.
Agreement allows for at-the-market offerings of ordinary shares under a Form S-3 registration statement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.